These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 12461164)

  • 1. T cells take aim at cancer.
    Pardoll D
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):15840-2. PubMed ID: 12461164
    [No Abstract]   [Full Text] [Related]  

  • 2. Strategies of lymphocyte activation for the adoptive immunotherapy of metastatic cancer: a review.
    Strome SE; Krauss JC; Chang AE; Shu S
    J Hematother; 1993; 2(1):63-73. PubMed ID: 7921967
    [No Abstract]   [Full Text] [Related]  

  • 3. Genetically engineered T cells as adoptive immunotherapy of cancer.
    Ma Q; Gonzalo-Daganzo RM; Junghans RP
    Cancer Chemother Biol Response Modif; 2002; 20():315-41. PubMed ID: 12703212
    [No Abstract]   [Full Text] [Related]  

  • 4. Tumor-infiltrating lymphocytes from human solid tumors: antigen-specific killer T lymphocytes of activated natural killer lymphocytes.
    Whiteside TL; Heo DS; Takagi S; Herberman RB
    Immunol Ser; 1989; 48():139-57. PubMed ID: 2488318
    [No Abstract]   [Full Text] [Related]  

  • 5. Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2.
    Nakamura Y; Wakimoto H; Abe J; Kanegae Y; Saito I; Aoyagi M; Hirakawa K; Hamada H
    Cancer Res; 1994 Nov; 54(22):5757-60. PubMed ID: 7525049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy.
    Besser MJ; Schallmach E; Oved K; Treves AJ; Markel G; Reiter Y; Schachter J
    Cytotherapy; 2009; 11(2):206-17. PubMed ID: 19148842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
    J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cell triumph. Immunotherapy may have finally turned a corner.
    Martindale D
    Sci Am; 2003 Feb; 288(2):12-3. PubMed ID: 12561452
    [No Abstract]   [Full Text] [Related]  

  • 9. Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.
    Kurnick JT; Kradin RL
    Allergol Immunopathol (Madr); 1991; 19(5):209-14. PubMed ID: 1811418
    [No Abstract]   [Full Text] [Related]  

  • 10. [Tumor antigens recognized by T-lymphocytes in human cancers. New advances and therapeutic perspectives].
    Gaugler B; Olive D
    Pathol Biol (Paris); 1998 Dec; 46(10):771-8. PubMed ID: 9922993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene therapy of cancer.
    Rosenberg SA
    Important Adv Oncol; 1992; ():17-38. PubMed ID: 1582673
    [No Abstract]   [Full Text] [Related]  

  • 12. [Application of gene therapy in tumor adoptive immunotherapy].
    Wang C; Zhao Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Apr; 25(2):482-6. PubMed ID: 18610648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of malignant melanoma.
    Oratz R; Bystryn JC
    Dermatol Clin; 1991 Oct; 9(4):669-82. PubMed ID: 1718648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
    Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
    Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive therapy with purified CD8 cells in HIV infection.
    Herberman RB
    Semin Hematol; 1992 Apr; 29(2 Suppl 1):35-40. PubMed ID: 1535457
    [No Abstract]   [Full Text] [Related]  

  • 16. Melanoma, vitiligo, and uveitis.
    Albert DM
    Ophthalmology; 2010 Mar; 117(3):643-4; author reply 644. PubMed ID: 20189042
    [No Abstract]   [Full Text] [Related]  

  • 17. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
    Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
    Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of T lymphocytes in the immunotherapy of tumours.
    Brondz BD; Balashov KE
    Biomed Sci; 1991; 2(5):441-9. PubMed ID: 1840832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience.
    Semino C; Martini L; Queirolo P; Cangemi G; Costa R; Alloisio A; Ferlazzo G; Sertoli MR; Reali UM; Ratto GB; Melioli G
    Anticancer Res; 1999; 19(6C):5645-9. PubMed ID: 10697634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
    Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
    Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.